Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting

SEATTLE and WASHINGTON, Oct. 1 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 25th International Society for Biological Therapy of Cancer (iSBTc) annual meeting in Washington, D.C.

  • "Sipulecel-T Immune Parameters and Correlation with Overall Survival." Session 2 of the Symposium on Immuno-Oncology Biomarkers, 2010 and Beyond: Correlation of Immunity to Clinical Response and Potency Assays from 10:00 a.m. to 12:00 p.m. EDT on Thursday, September 30, 2010.
  • "Progress in the Active Immunotherapy of Prostate Cancer: Sipuleucel-T, an Autologous Cellular Immunotherapy." Plenary Session: Dendritic Cells and Cancer from 9:15 to 9:45 a.m. EDT on Saturday, October 2, 2010.
  • "Characterization of Antigen Specific T-cell Activation and Cytokine Expression Induced by Sipuleucel-T." Poster presentation from 7:00 – 7:45 p.m. EDT on Saturday, October 2, 2010.

Data presented at the iSBTc annual meeting include data from the pivotal Phase 3 IMPACT study in which PROVENGE demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer (mCRPC).  

"The analyses from the pivotal Phase 3 IMPACT trial examining a subset of patients showed an enhanced immune response in patients treated with PROVENGE," said Mark Frohlich, M.D., senior vice president of clinical affairs and chief medical officer of Dendreon. "These findings provide further understanding of PROVENGE's proposed mechanism of action designed to stimulate a patient's immune system to identify and attack prostate cancer cells."

PROVENGE is the first product in a new therapeutic class known as autologous cellular immunotherapies to be approved by the U.S. Food and Drug Administration for the treatment of asymptomatic or minimally symptomatic metastatic castration resistant (hormone refractory) prostate cancer.

PROVENGE Important Safety Information

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis procedure. The most common adverse events (incidence greater than or equal to 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company's ongoing commitment to patients, Dendreon will conduct a registry with a target enrollment of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full Prescribing Information at or call Dendreon ON CALL at 1-877-336-3736.

About Active Cellular Immunotherapy

PROVENGE is classified by the FDA as an autologous cellular immunotherapy. It is designed to be an active cellular immunotherapy. Active cellular immunotherapy is designed to stimulate a T-cell response to cancer cells. An immune response is started by a specialized class of immune system cells called antigen-presenting cells (APCs). APCs take up antigens from their surroundings and process the antigens into fragments that are then displayed on the APC's surface. Once displayed, these antigens can be recognized by specific classes of immune cells called T lymphocytes (T-cells), which are activated as a result of their engagement with APCs and combat disease by seeking antigen-bearing cells directly. PROVENGE is designed to target the prostate cancer antigen prostatic acid phosphatase (PAP), an antigen that is expressed in more than 95 percent of all prostate cancers.

About Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
(Date:11/30/2015)... and REHOVOT, Israel , Nov. ... pharmaceutical company focused on acquiring and developing innovative therapies ... the appointment of Keith A. Katkin as ... Gregory J. Flesher , chief executive officer for OticPharma, ... successful organizations.  As chairman, he will be able to ...
(Date:11/30/2015)... 2015 Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ... Kentucky Breast Care to increase collaboration with sub-specialists around ... patients. --> Sectra (STO: SECT ... entered into a multi-year agreement to provide Breast Imaging ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... An inventor ... life in the womb. "My last baby had high blood pressure due to loud ... mothers to protect their babies from noise pollution as well as radio waves and ...
(Date:11/30/2015)... York (PRWEB) , ... November 30, 2015 , ... In ... of his role as a top ophthalmologist on Long Island’s east end. During the ... teaching, innovations in surgery and treatment of glaucoma and cataracts, and how a visit ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... and websites specializing in independent living, assisted living and all other retirement options. ... Alzheimer’s awareness and research remains a top priority. , So it’s ...
(Date:11/30/2015)... ... 30, 2015 , ... Holcomb – Kreithen Plastic Surgery ... practices in Florida, is proud to announce that Dr. Joshua Kreithen, one of ... Inc., a Johnson & Johnson Company. , Ethicon is a global medical device ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Sikka Software announced ... Dental Meeting. Their Ecosystem empowers dentists to make complex business decisions by providing the ... will receive a free fee survey with 10 procedures customized by zip code. ...
Breaking Medicine News(10 mins):